{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '9.6.3', 'Primary and Secondary Endpoint Analysis', 'The primary analyses will be conducted in the ITT population. The analysis of the primary', 'proptosis responder endpoint will assess risk difference (difference in response rates) in a', 'stratified analysis. The analysis will use Cochran-Mantel-Haenszel (CMH) weighting to', 'estimate the common risk difference within strata and to estimate the standard error of the', 'common risk difference. be a logistic regression with treatment group as the model effect.', 'Subjects missing the Week 24 evaluation will be considered to be treatment failures', '(non-responders) for the primary analysis. Further, subjects who prematurely discontinue', 'study drug dosing prior to Week 21 during the double-masked Treatment Period will be', 'considered to be treatment failures (non-responders), unless an assessment at Week 24', 'is', 'available. Stratification for the analysis will use the same factor as was used to stratify', 'randomization, tobacco use (non-user, user). Since tobacco use status (non user VS. user) is', 'used to stratify the randomization, it will be included as a categorical covariate. The difference', 'in response rates, comparing teprotumumab to placebo, will be estimated Odds ratio', 'comparing teprotumumal to placebo will be estimated along with the corresponding 95%', 'confidence interval (CI) and p-value.', 'An analysis of risk difference with stratification by tobacco use (non-user VS. user) Logistic', 'regressionwill also be used to analyze the 32-secondary categorical endpoints. For the analysis of', 'proptosis and GO-QoL (see Section 9.6.4.4 for details) as continuous secondary endpoints, a', 'Mixed-Model Repeated-Measures (MMRM) analysis of covariance (ANCOVA) model will be', 'fit to the individual change from baseline scores for the study eye, with terms in the model', 'being the baseline score, tobacco use status, treatment group, visit, and the visit-by-treatment and', 'visit-by-baseline-score interactions. The main focus of the analysis will be to test the treatment', 'differences at Week 24, with the main results consisting of the Week 24 estimated Least Square', '(LS) means and their differences with 95% CIs and p-values.', 'To control the overall Type 1 error rate of the study, taking into consideration the one primary', 'and 54-secondary outcome measures, the outcome measures will be tested in a hierarchical', 'stepwise fashion. For each outcome measure, teprotumumab will be tested against placebo at the', '0.05 level only if teprotumumab was statistically significant for the outcome measure preceding', 'it in the hierarchical order.', '9.6.4.2 Clinical Measures of Severity', 'The Clinical Measures of Severity results (see Table 9.3) for each item will be summarized at', 'each designated visit for each eye with the number and percentage of subjects being classified as', 'responders on each individual criterion. The proportions of responders will be analyzed using the', 'same risk difference method described for the primary endpoint a Chi square testin', 'Section 9.6.3.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 20 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '17.1', 'Administrative Appendix', 'Sponsor', 'Representative', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 21 of 117']\n\n###\n\n", "completion": "END"}